For the Inventor, By the Inventor

Enter inventor name

Shanghai, China

Charles Z Ding

USPTO Granted Patents = 50 (Patent Applications = 37)

EPO Patents = 34 (Patent Applications = 71)

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 23(Granted Patents)

Forward Citations (Not Self Cited) = 11(Dec 10, 2025)

Company Filing History:

Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Luoxin Pharmaceutical (shanghai) Co., Ltd.

Fujian Akeylink Biotechnology Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Fujian Cosunter Pharmaceutical Co., Ltd.

Harbin Zhenbao Pharmaceutical Co., Ltd.

Genfleet Therapeutics (shanghai) Inc.

Hubei Bio-pharmaceutical Industrial Technological Institute Inc.

Humanwell Healthcare (group) Co., Ltd.

Shenzhen Optimum Biological Technology Co., Ltd

12. 2 out of 13

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

13. 2 out of 11

Qilu Pharmaceutical Co., Ltd.

14. 1 out of 11

Nanjing Sanhome Pharmaceutical Co., Ltd.

Zhuohe Pharmaceutical Group Co., Ltd

China Resources Biopharmaceutical Company Limited

China Resources Pharmaceutical Holdings Company Limited

Cstone Pharmaceuticals

Wuxi Fortune Pharmaceutical Co., Ltd

Guangdong Zhongsheng Pharmaceutical Co., Ltd

Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

Loading Chart...

Areas of Expertise:

KRAS G12C Inhibitor

TGF-βR1 Kinase Inhibitor

Estrogen Receptor Antagonist

c-Met Inhibitor

Hepatitis B Surface Antigen Inhibitor

AKT Inhibitor

EGFR Kinase Inhibitor

IAP Inhibitor

β-Lactamase Inhibitor

JAK Inhibitor

Antibacterial Compounds

Pyrimidine Derivatives

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12491180 - Application of compound in treating pneumonia (2025-12-09),

2. 12435101 - Isochroman compound (2025-10-07),

3. 12421236 - Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor (2025-09-23),

4. 12391707 - Preparation method for oxazepine compound (2025-08-19),

5. 12338263 - Antibacterial aminoglycoside derivatives (2025-06-24),

6. 12325695 - 5-(4-pyridyloxy)pyrazole compounds serving as TGF-βR1 kinase inhibitor (2025-06-10),

7. 12310948 - Application of monocyclic β-lactam compound in pharmacy (2025-05-27),

8. 12221432 - Estrogen receptor antagonist (2025-02-11),

9. 12122780 - Pyrimidinyl group-containing tricyclic compound serving as c-Met inhibitor (2024-10-22),

10. 12103936 - Crystal form of hepatitis B surface antigen inhibitor (2024-10-01),

11. 12098127 - Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor (2024-09-24),

12. 12071435 - TLR8 agonist (2024-08-27),

13. 12054482 - TLR8 agonist (2024-08-06),

14. 12018027 - Macrocyclic derivatives acting as XIa factor inhibitor (2024-06-25),

15. 11807647 - Crystal form of hepatitis B surface antigen inhibitor and application thereof (2023-11-07),

Title: The Innovative Journey of Charles Z Ding

Introduction: Charles Z Ding is a renowned inventor hailing from Shanghai, China, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Charles Z Ding holds a series of recent patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his continuous commitment to innovation.

Career Highlights: With a distinguished career spanning over two decades, Charles Z Ding has worked with leading research institutions and multinational companies, playing a pivotal role in developing cutting-edge technologies that have revolutionized industries.

Collaborations: Throughout his career, Charles Z Ding has collaborated with top universities, research institutions, and forward-thinking companies, fostering a culture of innovation and knowledge exchange.

Conclusion: Charles Z Ding's passion for innovation, coupled with his relentless pursuit of excellence, has solidified his position as a trailblazer in the world of inventions, inspiring future generations of inventors to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…